<DOC>
	<DOCNO>NCT03042871</DOCNO>
	<brief_summary>The purpose study compare efficacy ( time injection , change visual acuity Cva/ I ) safety ( macular visual function choroidal thickness ) different dose ranibizumab intravitreal injection ( 1+PRN vs. 3+PRN ) treat pathological myopia choroidal neovascularization ( PM-CNV ) .</brief_summary>
	<brief_title>Dosing Strategy Intravitreal Ranibizumab Pathological Myopia Choroidal Neovascularization</brief_title>
	<detailed_description>PM common disease east asia , PM-CNV affect 5 % -10 % PM patients.PM-CNV specific characteristic , include small dimension limit exudative manifestation compare age-related macular degeneration . However , treatment regimen re-treatment criterion follow PrONTO protocol . The question optimal dose treatment regimen myopic CNV management still unresolved . There unequivocal evidence suggest hat PRN treatment effective loading phase follow as-needed variable dosage regimen .</detailed_description>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>old 18 year old refractive error ≥ 6.0 diopter axial length ≥ 26.0mm active CNV due high myopic reason cause visual loss confirm fluorescein fundus angiography BCVA ≥ 24.0 ≤73 letter start distance 4 meter use Early Treatment Diabetic Retinopathy Study visual acuity chart . history ( ) stroke , ( b ) laser photocoagulation involve macular area study eye , ( c ) intraocular treatment corticosteroid intraocular surgery anti vascular endothelial growth factor verteporfin photodynamic therapy within 6 month study eye , ( ) hypersensitivity ranibizumab fluorescein presence active infectious disease confirm intraocular pressure ≥ 21.0 mmHg pregnant nursing woman uncontrolled high blood pressure ≥ 150/90 mmHg uncontrolled fast blood glucose ≥ 7 mmol/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>PM-CNV , Ranibizumab , Dosing Strategy</keyword>
</DOC>